ID   APTX_HUMAN              Reviewed;         356 AA.
AC   Q7Z2E3; A8MTN4; D3DRK9; D3DRL0; Q0P662; Q5T781; Q5T782; Q5T784;
AC   Q6JV81; Q6JV82; Q6JV85; Q7Z2F3; Q7Z336; Q7Z5R5; Q7Z6V7; Q7Z6V8;
AC   Q9NXM5;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 2.
DT   04-FEB-2015, entry version 125.
DE   RecName: Full=Aprataxin;
DE            EC=3.-.-.-;
DE   AltName: Full=Forkhead-associated domain histidine triad-like protein;
DE            Short=FHA-HIT;
GN   Name=APTX; Synonyms=AXA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7; 12 AND 13), ALTERNATIVE
RP   SPLICING, AND SUBCELLULAR LOCATION.
RX   PubMed=15276230; DOI=10.1016/j.neulet.2004.05.034;
RA   Hirano M., Nishiwaki T., Kariya S., Furiya Y., Kawahara M., Ueno S.;
RT   "Novel splice variants increase molecular diversity of aprataxin, the
RT   gene responsible for early-onset ataxia with ocular motor apraxia and
RT   hypoalbuminemia.";
RL   Neurosci. Lett. 366:120-125(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Huang C.-H.;
RT   "Identification of FHA-HIT as a novel nuclear protein involved in
RT   cell-cycle regulation.";
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8 AND 10).
RC   TISSUE=Hypothalamus, Kidney, Lung adenocarcinoma, Lymphoma, Melanoma,
RC   Muscle, Retinoblastoma, Skin, and Testis;
RA   Chen Y., Huang C.-H.;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 11).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9).
RC   TISSUE=Endometrium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 4 AND 7).
RC   TISSUE=Brain, Lung, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-261 (ISOFORMS 2; 4; 5 AND 7).
RC   TISSUE=Brain;
RA   Hellenbroich Y., Habeck M.;
RT   "Mutations in the APTX gene.";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY, AND VARIANTS AOA LEU-220 AND GLY-277.
RX   PubMed=11586299; DOI=10.1038/ng1001-184;
RA   Date H., Onodera O., Tanaka H., Iwabuchi K., Uekawa K., Igarashi S.,
RA   Koike R., Hiroi T., Yuasa T., Awaya Y., Sakai T., Takahashi T.,
RA   Nagatomo H., Sekijima Y., Kawachi I., Takiyama Y., Nishizawa M.,
RA   Fukuhara N., Saito K., Sugano S., Tsuji S.;
RT   "Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is
RT   caused by mutations in a new HIT superfamily gene.";
RL   Nat. Genet. 29:184-188(2001).
RN   [11]
RP   ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND VARIANTS AOA HIS-213 AND
RP   LEU-220.
RX   PubMed=11586300; DOI=10.1038/ng1001-189;
RA   Moreira M.-C., Barbot C., Tachi N., Kozuka N., Uchida E., Gibson T.,
RA   Mendonca P., Costa M., Barros J., Yanagisawa T., Watanabe M.,
RA   Ikeda Y., Aoki M., Nagata T., Coutinho P., Sequeiros J., Koenig M.;
RT   "The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-
RT   finger protein aprataxin.";
RL   Nat. Genet. 29:189-193(2001).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION
RP   WITH XRCC1.
RX   PubMed=14755728; DOI=10.1002/ana.10808;
RA   Sano Y., Date H., Igarashi S., Onodera O., Oyake M., Takahashi T.,
RA   Hayashi S., Morimatsu M., Takahashi H., Makifuchi T., Fukuhara N.,
RA   Tsuji S.;
RT   "Aprataxin, the causative protein for EAOH is a nuclear protein with a
RT   potential role as a DNA repair protein.";
RL   Ann. Neurol. 55:241-249(2004).
RN   [13]
RP   INTERACTION WITH XRCC1 AND XRCC4, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ARG-43.
RX   PubMed=15380105; DOI=10.1016/j.dnarep.2004.06.017;
RA   Clements P.M., Breslin C., Deeks E.D., Byrd P.J., Ju L.,
RA   Bieganowski P., Brenner C., Moreira M.-C., Taylor A.M.R.,
RA   Caldecott K.W.;
RT   "The ataxia-oculomotor apraxia 1 gene product has a role distinct from
RT   ATM and interacts with the DNA strand break repair proteins XRCC1 and
RT   XRCC4.";
RL   DNA Repair 3:1493-1502(2004).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH XRCC1; ADPRT;
RP   TP53 AND NCL.
RX   PubMed=15044383; DOI=10.1093/hmg/ddh122;
RA   Gueven N., Becherel O.J., Kijas A.W., Chen P., Howe O., Rudolph J.H.,
RA   Gatti R., Date H., Onodera O., Taucher-Scholz G., Lavin M.F.;
RT   "Aprataxin, a novel protein that protects against genotoxic stress.";
RL   Hum. Mol. Genet. 13:1081-1093(2004).
RN   [15]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH XRCC1 AND NCL.
RX   PubMed=16777843; DOI=10.1093/hmg/ddl149;
RA   Becherel O.J., Gueven N., Birrell G.W., Schreiber V., Suraweera A.,
RA   Jakob B., Taucher-Scholz G., Lavin M.F.;
RT   "Nucleolar localization of aprataxin is dependent on interaction with
RT   nucleolin and on active ribosomal DNA transcription.";
RL   Hum. Mol. Genet. 15:2239-2249(2006).
RN   [16]
RP   FUNCTION, DNA-BINDING, AND CHARACTERIZATION OF VARIANT GLY-277.
RX   PubMed=16547001; DOI=10.1074/jbc.M507946200;
RA   Kijas A.W., Harris J.L., Harris J.M., Lavin M.F.;
RT   "Aprataxin forms a discrete branch in the HIT (histidine triad)
RT   superfamily of proteins with both DNA/RNA binding and nucleotide
RT   hydrolase activities.";
RL   J. Biol. Chem. 281:13939-13948(2006).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF HIS-274.
RX   PubMed=16964241; DOI=10.1038/nature05164;
RA   Ahel I., Rass U., El-Khamisy S.F., Katyal S., Clements P.M.,
RA   McKinnon P.J., Caldecott K.W., West S.C.;
RT   "The neurodegenerative disease protein aprataxin resolves abortive DNA
RT   ligation intermediates.";
RL   Nature 443:713-716(2006).
RN   [18]
RP   FUNCTION, AND MUTAGENESIS OF HIS-274; CYS-333 AND CYS-336.
RX   PubMed=17276982; DOI=10.1074/jbc.M611489200;
RA   Rass U., Ahel I., West S.C.;
RT   "Actions of aprataxin in multiple DNA repair pathways.";
RL   J. Biol. Chem. 282:9469-9474(2007).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-132, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 15-116, SUBCELLULAR
RP   LOCATION, INTERACTION WITH MDC1, AND MUTAGENESIS OF ARG-43 AND LYS-52.
RX   PubMed=20008512; DOI=10.1093/nar/gkp1149;
RA   Becherel O.J., Jakob B., Cherry A.L., Gueven N., Fusser M.,
RA   Kijas A.W., Peng C., Katyal S., McKinnon P.J., Chen J., Epe B.,
RA   Smerdon S.J., Taucher-Scholz G., Lavin M.F.;
RT   "CK2 phosphorylation-dependent interaction between aprataxin and MDC1
RT   in the DNA damage response.";
RL   Nucleic Acids Res. 38:1489-1503(2010).
RN   [21]
RP   VARIANT AOA ARG-215.
RX   PubMed=12196655; DOI=10.1212/WNL.59.4.590;
RA   Shimazaki H., Takiyama Y., Sakoe K., Ikeguchi K., Niijima K.,
RA   Kaneko J., Namekawa M., Ogawa T., Date H., Tsuji S., Nakano I.,
RA   Nishizawa M.;
RT   "Early-onset ataxia with ocular motor apraxia and hypoalbuminemia: the
RT   aprataxin gene mutations.";
RL   Neurology 59:590-595(2002).
RN   [22]
RP   VARIANT AOA GLN-211.
RX   PubMed=12629250; DOI=10.1212/01.WNL.0000048562.88536.A4;
RA   Tranchant C., Fleury M., Moreira M.-C., Koenig M., Warter J.-M.;
RT   "Phenotypic variability of aprataxin gene mutations.";
RL   Neurology 60:868-870(2003).
RN   [23]
RP   VARIANTS AOA VAL-212; GLY-277 AND ARG-293.
RX   PubMed=14506070; DOI=10.1093/brain/awg283;
RA   Le Ber I., Moreira M.-C., Rivaud-Pechoux S., Chamayou C., Ochsner F.,
RA   Kuntzer T., Tardieu M., Saied G., Habert M.-O., Demarquay G.,
RA   Tannier C., Beis J.-M., Brice A., Koenig M., Duerr A.;
RT   "Cerebellar ataxia with oculomotor apRAxia type 1: clinical and
RT   genetic studies.";
RL   Brain 126:2761-2772(2003).
RN   [24]
RP   VARIANT AOA PRO-237.
RX   PubMed=15852392; DOI=10.1002/ana.20463;
RA   Criscuolo C., Mancini P., Menchise V., Sacca F., De Michele G.,
RA   Banfi S., Filla A.;
RT   "Very late onset in ataxia oculomotor apraxia type I.";
RL   Ann. Neurol. 57:777-777(2005).
RN   [25]
RP   INVOLVEMENT IN AOA.
RX   PubMed=15699391; DOI=10.1212/01.WNL.0000150588.75281.58;
RA   Quinzii C.M., Kattah A.G., Naini A., Akman H.O., Mootha V.K.,
RA   DiMauro S., Hirano M.;
RT   "Coenzyme Q deficiency and cerebellar ataxia associated with an
RT   aprataxin mutation.";
RL   Neurology 64:539-541(2005).
CC   -!- FUNCTION: DNA-binding protein involved in single-strand DNA break
CC       repair, double-strand DNA break repair and base excision repair.
CC       Resolves abortive DNA ligation intermediates formed either at base
CC       excision sites, or when DNA ligases attempt to repair non-
CC       ligatable breaks induced by reactive oxygen species. Catalyzes the
CC       release of adenylate groups covalently linked to 5'-phosphate
CC       termini, resulting in the production of 5'-phosphate termini that
CC       can be efficiently rejoined. Also able to hydrolyze adenosine 5'-
CC       monophosphoramidate (AMP-NH(2)) and diadenosine tetraphosphate
CC       (AppppA), but with lower catalytic activity.
CC       {ECO:0000269|PubMed:14755728, ECO:0000269|PubMed:15044383,
CC       ECO:0000269|PubMed:16547001, ECO:0000269|PubMed:16964241,
CC       ECO:0000269|PubMed:17276982}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18 uM for AppppA;
CC         KM=837.5 uM for AMP-NH(2);
CC   -!- SUBUNIT: Interacts with single-strand break repair proteins XRCC1,
CC       XRCC4, ADPRT and p53/TP53. Interacts with NCL. Interacts (via FHA-
CC       like domain) with MDC1 (phosphorylated).
CC       {ECO:0000269|PubMed:14755728, ECO:0000269|PubMed:15044383,
CC       ECO:0000269|PubMed:15380105, ECO:0000269|PubMed:16777843,
CC       ECO:0000269|PubMed:20008512}.
CC   -!- INTERACTION:
CC       P09874:PARP1; NbExp=8; IntAct=EBI-847814, EBI-355676;
CC       P18887:XRCC1; NbExp=11; IntAct=EBI-847814, EBI-947466;
CC       Q13426:XRCC4; NbExp=3; IntAct=EBI-847814, EBI-717592;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm. Nucleus, nucleolus.
CC       Note=Upon genotoxic stress, colocalizes with XRCC1 at sites of DNA
CC       damage. Colocalizes with MDC1 at sites of DNA double-strand
CC       breaks. Interaction with NCL is required for nucleolar
CC       localization.
CC   -!- SUBCELLULAR LOCATION: Isoform 12: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=13;
CC       Name=1; Synonyms=Long;
CC         IsoId=Q7Z2E3-1; Sequence=Displayed;
CC         Note=Major form.;
CC       Name=2; Synonyms=Short;
CC         IsoId=Q7Z2E3-2; Sequence=VSP_010535;
CC         Note=Minor form.;
CC       Name=3;
CC         IsoId=Q7Z2E3-3; Sequence=VSP_010539;
CC         Note=May be an aberrant isoform present in cancer cell lines.;
CC       Name=4;
CC         IsoId=Q7Z2E3-4; Sequence=VSP_010536;
CC         Note=May be an aberrant isoform present in cancer cell lines.;
CC       Name=5;
CC         IsoId=Q7Z2E3-5; Sequence=VSP_010537, VSP_010538;
CC         Note=May be an aberrant isoform present in cancer cell lines.;
CC       Name=6;
CC         IsoId=Q7Z2E3-6; Sequence=VSP_010534, VSP_010541;
CC         Note=May be an aberrant isoform present in cancer cell lines.;
CC       Name=7;
CC         IsoId=Q7Z2E3-7; Sequence=VSP_010537;
CC       Name=8;
CC         IsoId=Q7Z2E3-8; Sequence=VSP_010540;
CC         Note=May be an aberrant isoform present in cancer cell lines.;
CC       Name=9;
CC         IsoId=Q7Z2E3-9; Sequence=VSP_010537, VSP_010541;
CC         Note=No experimental confirmation available.;
CC       Name=10;
CC         IsoId=Q7Z2E3-10; Sequence=VSP_010538;
CC         Note=May be an aberrant isoform present in cancer cell lines.;
CC       Name=11;
CC         IsoId=Q7Z2E3-11; Sequence=VSP_010541;
CC         Note=No experimental confirmation available.;
CC       Name=12; Synonyms=LP2, LP2E5, LP2P3, LP2P3E5;
CC         IsoId=Q7Z2E3-12; Sequence=VSP_010537, VSP_044091, VSP_044092;
CC       Name=13; Synonyms=LE5;
CC         IsoId=Q7Z2E3-13; Sequence=VSP_010537, VSP_044093;
CC   -!- TISSUE SPECIFICITY: Widely expressed. In brain, it is expressed in
CC       the posterior cortex, cerebellum, hippocampus and olfactory bulb.
CC       Isoform 1 is highly expressed in the cerebral cortex and
CC       cerebellum, compared to isoform 2. {ECO:0000269|PubMed:11586299,
CC       ECO:0000269|PubMed:11586300, ECO:0000269|PubMed:14755728}.
CC   -!- DOMAIN: The histidine triad, also called HIT motif, forms part of
CC       the binding loop for the alpha-phosphate of purine mononucleotide.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The FHA-like domain mediates interaction with NCL; XRCC1
CC       and XRCC4.
CC   -!- DOMAIN: The HIT domain is required for enzymatic activity.
CC   -!- DOMAIN: The C2H2-type zinc finger mediates DNA-binding.
CC   -!- DISEASE: Ataxia-oculomotor apraxia syndrome (AOA) [MIM:208920]: An
CC       autosomal recessive syndrome characterized by early-onset
CC       cerebellar ataxia, oculomotor apraxia, early areflexia and late
CC       peripheral neuropathy. {ECO:0000269|PubMed:11586299,
CC       ECO:0000269|PubMed:11586300, ECO:0000269|PubMed:12196655,
CC       ECO:0000269|PubMed:12629250, ECO:0000269|PubMed:14506070,
CC       ECO:0000269|PubMed:15699391, ECO:0000269|PubMed:15852392}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Contains 1 C2H2-type zinc finger. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 FHA-like domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 HIT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00464}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY302067; AAQ74130.1; -; mRNA.
DR   EMBL; AY302068; AAQ74131.1; -; mRNA.
DR   EMBL; AY302070; AAQ74133.1; -; mRNA.
DR   EMBL; AY302071; AAQ74134.1; -; mRNA.
DR   EMBL; AY302072; AAQ74135.1; -; mRNA.
DR   EMBL; AY302074; AAQ74137.1; -; mRNA.
DR   EMBL; AY040777; AAK91768.1; -; mRNA.
DR   EMBL; AY208829; AAP86319.1; -; mRNA.
DR   EMBL; AY208830; AAP86320.1; -; mRNA.
DR   EMBL; AY208831; AAP86321.1; -; mRNA.
DR   EMBL; AY208832; AAP86322.1; -; mRNA.
DR   EMBL; AY208833; AAP86323.1; -; mRNA.
DR   EMBL; AY208834; AAP86324.1; -; mRNA.
DR   EMBL; AY208835; AAP86325.1; -; mRNA.
DR   EMBL; AY208836; AAP86326.1; -; mRNA.
DR   EMBL; AY208837; AAP86327.1; -; mRNA.
DR   EMBL; AY208838; AAP86328.1; -; mRNA.
DR   EMBL; AY208839; AAP86329.1; -; mRNA.
DR   EMBL; AY208840; AAP86330.1; -; mRNA.
DR   EMBL; AY208841; AAP86331.1; -; mRNA.
DR   EMBL; AY208842; AAP86332.1; -; mRNA.
DR   EMBL; AK000164; BAA90985.1; -; mRNA.
DR   EMBL; AK055672; BAG51552.1; -; mRNA.
DR   EMBL; BX538161; CAD98041.1; -; mRNA.
DR   EMBL; AL162590; CAI15549.1; -; Genomic_DNA.
DR   EMBL; AL353717; CAI15549.1; JOINED; Genomic_DNA.
DR   EMBL; AL162590; CAI15551.1; -; Genomic_DNA.
DR   EMBL; AL353717; CAI15551.1; JOINED; Genomic_DNA.
DR   EMBL; AL353717; CAI15728.1; -; Genomic_DNA.
DR   EMBL; AL162590; CAI15728.1; JOINED; Genomic_DNA.
DR   EMBL; AL353717; CAI15730.1; -; Genomic_DNA.
DR   EMBL; AL162590; CAI15730.1; JOINED; Genomic_DNA.
DR   EMBL; AL353717; CAI15734.1; -; Genomic_DNA.
DR   EMBL; AL353717; CAI15735.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58530.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58529.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58531.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58532.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58534.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58535.1; -; Genomic_DNA.
DR   EMBL; BC001628; AAH01628.1; -; mRNA.
DR   EMBL; BC032650; AAH32650.1; -; mRNA.
DR   EMBL; BC104881; AAI04882.1; -; mRNA.
DR   EMBL; AJ565850; CAD92454.1; -; mRNA.
DR   EMBL; AJ565851; CAD92455.1; -; mRNA.
DR   EMBL; AJ565852; CAD92456.1; -; mRNA.
DR   EMBL; AJ565853; CAD92457.1; -; mRNA.
DR   EMBL; AJ565854; CAD92458.1; -; mRNA.
DR   EMBL; AJ565855; CAD92459.1; -; mRNA.
DR   EMBL; AJ575566; CAE01427.1; -; mRNA.
DR   CCDS; CCDS47956.1; -. [Q7Z2E3-7]
DR   CCDS; CCDS56568.1; -. [Q7Z2E3-10]
DR   CCDS; CCDS75827.1; -. [Q7Z2E3-5]
DR   RefSeq; NP_001182177.1; NM_001195248.1. [Q7Z2E3-1]
DR   RefSeq; NP_001182178.1; NM_001195249.1. [Q7Z2E3-7]
DR   RefSeq; NP_001182179.1; NM_001195250.1. [Q7Z2E3-10]
DR   RefSeq; NP_001182180.1; NM_001195251.1. [Q7Z2E3-9]
DR   RefSeq; NP_001182181.1; NM_001195252.1. [Q7Z2E3-3]
DR   RefSeq; NP_001182183.1; NM_001195254.1. [Q7Z2E3-5]
DR   RefSeq; NP_778239.1; NM_175069.2. [Q7Z2E3-11]
DR   RefSeq; NP_778243.1; NM_175073.2. [Q7Z2E3-7]
DR   RefSeq; XP_006716854.1; XM_006716791.1. [Q7Z2E3-7]
DR   RefSeq; XP_006716855.1; XM_006716792.1. [Q7Z2E3-4]
DR   UniGene; Hs.20158; -.
DR   PDB; 3KT9; X-ray; 1.65 A; A=15-116.
DR   PDB; 4NDF; X-ray; 1.94 A; A/B=179-356.
DR   PDB; 4NDG; X-ray; 2.54 A; A/B=179-356.
DR   PDB; 4NDH; X-ray; 1.85 A; A/B=179-356.
DR   PDB; 4NDI; X-ray; 1.90 A; A/B=179-356.
DR   PDBsum; 3KT9; -.
DR   PDBsum; 4NDF; -.
DR   PDBsum; 4NDG; -.
DR   PDBsum; 4NDH; -.
DR   PDBsum; 4NDI; -.
DR   ProteinModelPortal; Q7Z2E3; -.
DR   SMR; Q7Z2E3; 15-116, 178-354.
DR   BioGrid; 120191; 24.
DR   IntAct; Q7Z2E3; 16.
DR   MINT; MINT-1205251; -.
DR   PhosphoSite; Q7Z2E3; -.
DR   DMDM; 48428038; -.
DR   MaxQB; Q7Z2E3; -.
DR   PaxDb; Q7Z2E3; -.
DR   PRIDE; Q7Z2E3; -.
DR   DNASU; 54840; -.
DR   Ensembl; ENST00000309615; ENSP00000311547; ENSG00000137074. [Q7Z2E3-5]
DR   Ensembl; ENST00000379817; ENSP00000369145; ENSG00000137074. [Q7Z2E3-7]
DR   Ensembl; ENST00000379819; ENSP00000369147; ENSG00000137074. [Q7Z2E3-1]
DR   Ensembl; ENST00000379825; ENSP00000369153; ENSG00000137074. [Q7Z2E3-11]
DR   Ensembl; ENST00000397172; ENSP00000380357; ENSG00000137074. [Q7Z2E3-3]
DR   Ensembl; ENST00000436040; ENSP00000400806; ENSG00000137074. [Q7Z2E3-7]
DR   Ensembl; ENST00000460940; ENSP00000418311; ENSG00000137074. [Q7Z2E3-12]
DR   Ensembl; ENST00000463596; ENSP00000419846; ENSG00000137074. [Q7Z2E3-7]
DR   Ensembl; ENST00000467331; ENSP00000418733; ENSG00000137074. [Q7Z2E3-12]
DR   Ensembl; ENST00000468275; ENSP00000420263; ENSG00000137074. [Q7Z2E3-7]
DR   Ensembl; ENST00000472896; ENSP00000417804; ENSG00000137074. [Q7Z2E3-12]
DR   Ensembl; ENST00000476858; ENSP00000419042; ENSG00000137074. [Q7Z2E3-10]
DR   Ensembl; ENST00000479656; ENSP00000420071; ENSG00000137074. [Q7Z2E3-12]
DR   Ensembl; ENST00000482687; ENSP00000419289; ENSG00000137074. [Q7Z2E3-13]
DR   Ensembl; ENST00000485479; ENSP00000418144; ENSG00000137074. [Q7Z2E3-12]
DR   Ensembl; ENST00000494649; ENSP00000417634; ENSG00000137074. [Q7Z2E3-12]
DR   Ensembl; ENST00000495360; ENSP00000419623; ENSG00000137074. [Q7Z2E3-12]
DR   GeneID; 54840; -.
DR   KEGG; hsa:54840; -.
DR   UCSC; uc003zrj.3; human. [Q7Z2E3-1]
DR   UCSC; uc003zrl.3; human. [Q7Z2E3-2]
DR   UCSC; uc003zrr.3; human. [Q7Z2E3-5]
DR   UCSC; uc003zru.3; human. [Q7Z2E3-10]
DR   UCSC; uc003zrv.3; human. [Q7Z2E3-11]
DR   UCSC; uc003zrw.3; human. [Q7Z2E3-3]
DR   UCSC; uc003zrx.3; human. [Q7Z2E3-9]
DR   CTD; 54840; -.
DR   GeneCards; GC09M032962; -.
DR   GeneReviews; APTX; -.
DR   HGNC; HGNC:15984; APTX.
DR   HPA; HPA055545; -.
DR   MIM; 208920; phenotype.
DR   MIM; 606350; gene.
DR   neXtProt; NX_Q7Z2E3; -.
DR   Orphanet; 1168; Ataxia - oculomotor apraxia type 1.
DR   PharmGKB; PA24915; -.
DR   eggNOG; NOG278510; -.
DR   GeneTree; ENSGT00570000079163; -.
DR   HOGENOM; HOG000248858; -.
DR   HOVERGEN; HBG050555; -.
DR   InParanoid; Q7Z2E3; -.
DR   KO; K10863; -.
DR   OMA; PGQVLHM; -.
DR   OrthoDB; EOG786H3J; -.
DR   PhylomeDB; Q7Z2E3; -.
DR   TreeFam; TF313308; -.
DR   SABIO-RK; Q7Z2E3; -.
DR   ChiTaRS; APTX; human.
DR   EvolutionaryTrace; Q7Z2E3; -.
DR   GeneWiki; Aprataxin; -.
DR   GenomeRNAi; 54840; -.
DR   NextBio; 57644; -.
DR   PRO; PR:Q7Z2E3; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; Q7Z2E3; -.
DR   CleanEx; HS_APTX; -.
DR   ExpressionAtlas; Q7Z2E3; baseline and differential.
DR   Genevestigator; Q7Z2E3; -.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0033699; F:DNA 5'-adenosine monophosphate hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008967; F:phosphoglycolate phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0046403; F:polynucleotide 3'-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0016311; P:dephosphorylation; IDA:GOC.
DR   GO; GO:0000738; P:DNA catabolic process, exonucleolytic; IDA:GOC.
DR   GO; GO:0006266; P:DNA ligation; IEA:Ensembl.
DR   GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB.
DR   GO; GO:0098506; P:polynucleotide 3' dephosphorylation; IDA:GOC.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IDA:UniProtKB.
DR   GO; GO:0000012; P:single strand break repair; IDA:UniProtKB.
DR   Gene3D; 2.60.200.20; -; 2.
DR   Gene3D; 3.30.428.10; -; 1.
DR   InterPro; IPR026963; Aprataxin.
DR   InterPro; IPR000253; FHA_dom.
DR   InterPro; IPR019808; Histidine_triad_CS.
DR   InterPro; IPR001310; Histidine_triad_HIT.
DR   InterPro; IPR011146; HIT-like.
DR   InterPro; IPR008984; SMAD_FHA_domain.
DR   InterPro; IPR007087; Znf_C2H2.
DR   InterPro; IPR015880; Znf_C2H2-like.
DR   PANTHER; PTHR12486; PTHR12486; 1.
DR   PANTHER; PTHR12486:SF4; PTHR12486:SF4; 1.
DR   SMART; SM00355; ZnF_C2H2; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   SUPFAM; SSF54197; SSF54197; 1.
DR   PROSITE; PS00892; HIT_1; 1.
DR   PROSITE; PS51084; HIT_2; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Disease mutation; DNA damage; DNA repair; DNA-binding; Hydrolase;
KW   Metal-binding; Neurodegeneration; Nucleus; Phosphoprotein;
KW   Reference proteome; Zinc; Zinc-finger.
FT   CHAIN         1    356       Aprataxin.
FT                                /FTId=PRO_0000109838.
FT   DOMAIN       38     87       FHA-like.
FT   DOMAIN      182    287       HIT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00464}.
FT   ZN_FING     331    353       C2H2-type.
FT   REGION        1    110       Interactions with ADPRT and NCL.
FT   MOTIF       126    131       Nuclear localization signal.
FT                                {ECO:0000305}.
FT   MOTIF       272    276       Histidine triad motif.
FT   ACT_SITE    274    274       Tele-AMP-histidine intermediate.
FT                                {ECO:0000305}.
FT   MOD_RES     132    132       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   VAR_SEQ       1    193       Missing (in isoform 6).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_010534.
FT   VAR_SEQ       1    188       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.3, ECO:0000303|Ref.9}.
FT                                /FTId=VSP_010535.
FT   VAR_SEQ       1    102       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.3, ECO:0000303|Ref.9}.
FT                                /FTId=VSP_010536.
FT   VAR_SEQ       1     14       Missing (in isoform 5, isoform 7, isoform
FT                                9, isoform 12 and isoform 13).
FT                                {ECO:0000303|PubMed:15276230,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|Ref.3, ECO:0000303|Ref.9}.
FT                                /FTId=VSP_010537.
FT   VAR_SEQ      59    112       Missing (in isoform 5 and isoform 10).
FT                                {ECO:0000303|Ref.3, ECO:0000303|Ref.9}.
FT                                /FTId=VSP_010538.
FT   VAR_SEQ      60     63       QLKA -> ESRV (in isoform 12).
FT                                {ECO:0000303|PubMed:15276230}.
FT                                /FTId=VSP_044091.
FT   VAR_SEQ      64    356       Missing (in isoform 12).
FT                                {ECO:0000303|PubMed:15276230}.
FT                                /FTId=VSP_044092.
FT   VAR_SEQ     104    175       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_010539.
FT   VAR_SEQ     175    193       Missing (in isoform 8).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_010540.
FT   VAR_SEQ     196    356       VYKDEQVVVIKDKYPKARYHWLVLPWTSISSLKAVAREHLE
FT                                LLKHMHTVGEKVIVDFAGSSKLRFRLGYHAIPSMSHVHLHV
FT                                ISQDFDSPCLKNKKHWNSFNTEYFLESQAVIEMVQEAGRVT
FT                                VRDGMPELLKLPLRCHECQQLLPSIPQLKEHLRKHWTQ ->
FT                                PCTSSCDQPGF (in isoform 13).
FT                                {ECO:0000303|PubMed:15276230}.
FT                                /FTId=VSP_044093.
FT   VAR_SEQ     306    356       AVIEMVQEAGRVTVRDGMPELLKLPLRCHECQQLLPSIPQL
FT                                KEHLRKHWTQ -> E (in isoform 6, isoform 9
FT                                and isoform 11).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_010541.
FT   VARIANT     211    211       K -> Q (in AOA; it probably does not
FT                                greatly affect the protein;
FT                                heterozygous).
FT                                {ECO:0000269|PubMed:12629250}.
FT                                /FTId=VAR_018794.
FT   VARIANT     212    212       A -> V (in AOA; heterozygous).
FT                                {ECO:0000269|PubMed:14506070}.
FT                                /FTId=VAR_018795.
FT   VARIANT     213    213       R -> H (in AOA; dbSNP:rs150886026).
FT                                {ECO:0000269|PubMed:11586300}.
FT                                /FTId=VAR_018796.
FT   VARIANT     215    215       H -> R (in AOA).
FT                                {ECO:0000269|PubMed:12196655}.
FT                                /FTId=VAR_018797.
FT   VARIANT     220    220       P -> L (in AOA).
FT                                {ECO:0000269|PubMed:11586299,
FT                                ECO:0000269|PubMed:11586300}.
FT                                /FTId=VAR_018798.
FT   VARIANT     237    237       L -> P (in AOA).
FT                                {ECO:0000269|PubMed:15852392}.
FT                                /FTId=VAR_025365.
FT   VARIANT     277    277       V -> G (in AOA; abolishes DNA-binding and
FT                                enzymatic activity towards Ap(4)A).
FT                                {ECO:0000269|PubMed:11586299,
FT                                ECO:0000269|PubMed:14506070,
FT                                ECO:0000269|PubMed:16547001}.
FT                                /FTId=VAR_018799.
FT   VARIANT     281    281       D -> G (in AOA; heterozygous).
FT                                /FTId=VAR_018800.
FT   VARIANT     293    293       W -> R (in AOA; heterozygous).
FT                                {ECO:0000269|PubMed:14506070}.
FT                                /FTId=VAR_018801.
FT   MUTAGEN      43     43       R->A: Impairs interaction with XRCC1 and
FT                                XRCC4. Abolishes localization at sites of
FT                                DNA double-strand breaks. Loss of
FT                                interaction with MDC1.
FT                                {ECO:0000269|PubMed:15380105,
FT                                ECO:0000269|PubMed:20008512}.
FT   MUTAGEN      52     52       K->A: Impairs interaction with MDC1 and
FT                                localization at sites of DNA double-
FT                                strand breaks.
FT                                {ECO:0000269|PubMed:20008512}.
FT   MUTAGEN     274    274       H->A: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:16964241,
FT                                ECO:0000269|PubMed:17276982}.
FT   MUTAGEN     333    333       C->A: Abolishes DNA-binding and enzyme
FT                                activity; when associated with A-336.
FT                                {ECO:0000269|PubMed:17276982}.
FT   MUTAGEN     336    336       C->A: Abolishes DNA-binding and enzyme
FT                                activity; when associated with A-333.
FT                                {ECO:0000269|PubMed:17276982}.
FT   STRAND       18     23       {ECO:0000244|PDB:3KT9}.
FT   STRAND       30     32       {ECO:0000244|PDB:3KT9}.
FT   STRAND       38     41       {ECO:0000244|PDB:3KT9}.
FT   TURN         45     47       {ECO:0000244|PDB:3KT9}.
FT   STRAND       59     64       {ECO:0000244|PDB:3KT9}.
FT   TURN         65     68       {ECO:0000244|PDB:3KT9}.
FT   STRAND       69     74       {ECO:0000244|PDB:3KT9}.
FT   STRAND       76     78       {ECO:0000244|PDB:3KT9}.
FT   STRAND       92     95       {ECO:0000244|PDB:3KT9}.
FT   STRAND      101    104       {ECO:0000244|PDB:3KT9}.
FT   STRAND      107    115       {ECO:0000244|PDB:3KT9}.
FT   HELIX       181    183       {ECO:0000244|PDB:4NDH}.
FT   HELIX       184    188       {ECO:0000244|PDB:4NDH}.
FT   TURN        192    194       {ECO:0000244|PDB:4NDH}.
FT   STRAND      195    198       {ECO:0000244|PDB:4NDH}.
FT   STRAND      200    206       {ECO:0000244|PDB:4NDH}.
FT   STRAND      211    222       {ECO:0000244|PDB:4NDH}.
FT   HELIX       227    229       {ECO:0000244|PDB:4NDH}.
FT   HELIX       232    234       {ECO:0000244|PDB:4NDH}.
FT   HELIX       235    253       {ECO:0000244|PDB:4NDH}.
FT   HELIX       254    256       {ECO:0000244|PDB:4NDH}.
FT   STRAND      260    267       {ECO:0000244|PDB:4NDH}.
FT   STRAND      269    272       {ECO:0000244|PDB:4NDH}.
FT   STRAND      275    279       {ECO:0000244|PDB:4NDH}.
FT   HELIX       290    297       {ECO:0000244|PDB:4NDH}.
FT   STRAND      301    303       {ECO:0000244|PDB:4NDH}.
FT   HELIX       304    314       {ECO:0000244|PDB:4NDH}.
FT   HELIX       323    326       {ECO:0000244|PDB:4NDH}.
FT   TURN        334    336       {ECO:0000244|PDB:4NDH}.
FT   STRAND      339    342       {ECO:0000244|PDB:4NDH}.
FT   HELIX       343    350       {ECO:0000244|PDB:4NDH}.
FT   HELIX       351    353       {ECO:0000244|PDB:4NDH}.
SQ   SEQUENCE   356 AA;  40740 MW;  5B338490E35EC8E4 CRC64;
     MSNVNLSVSD FWRVMMRVCW LVRQDSRHQR IRLPHLEAVV IGRGPETKIT DKKCSRQQVQ
     LKAECNKGYV KVKQVGVNPT SIDSVVIGKD QEVKLQPGQV LHMVNELYPY IVEFEEEAKN
     PGLETHRKRK RSGNSDSIER DAAQEAEAGT GLEPGSNSGQ CSVPLKKGKD APIKKESLGH
     WSQGLKISMQ DPKMQVYKDE QVVVIKDKYP KARYHWLVLP WTSISSLKAV AREHLELLKH
     MHTVGEKVIV DFAGSSKLRF RLGYHAIPSM SHVHLHVISQ DFDSPCLKNK KHWNSFNTEY
     FLESQAVIEM VQEAGRVTVR DGMPELLKLP LRCHECQQLL PSIPQLKEHL RKHWTQ
//
